Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Denali Therapeutics (DNLI) Operating Expenses: 2017-2024

Historic Operating Expenses for Denali Therapeutics (DNLI) over the last 8 years, with Dec 2024 value amounting to $129.8 million.

  • Denali Therapeutics' Operating Expenses fell 2.06% to $129.8 million in Q4 2024 from the same period last year, while for Dec 2024 it was $501.9 million, marking a year-over-year decrease of 4.81%. This contributed to the annual value of $501.9 million for FY2024, which is 4.81% down from last year.
  • As of Q4 2024, Denali Therapeutics' Operating Expenses stood at $129.8 million, which was up 5.41% from $123.2 million recorded in Q3 2024.
  • In the past 5 years, Denali Therapeutics' Operating Expenses ranged from a high of $156.0 million in Q1 2023 and a low of $63.6 million during Q1 2020.
  • In the last 3 years, Denali Therapeutics' Operating Expenses had a median value of $119.9 million in 2024 and averaged $123.2 million.
  • As far as peak fluctuations go, Denali Therapeutics' Operating Expenses soared by 43.55% in 2023, and later fell by 15.20% in 2024.
  • Denali Therapeutics' Operating Expenses (Quarterly) stood at $72.7 million in 2020, then climbed by 23.23% to $89.6 million in 2021, then increased by 29.00% to $115.6 million in 2022, then rose by 14.65% to $132.6 million in 2023, then decreased by 2.06% to $129.8 million in 2024.
  • Its last three reported values are $129.8 million in Q4 2024, $123.2 million for Q3 2024, and $116.6 million during Q2 2024.